AUA 2022 | Mechanism of action of the adenovirus oncolytic virus CG0070 plus pembrolizumab in bladder cancer
Roger Li
• 23 May 2022
Roger Li, MD, Moffitt Cancer Center, Tampa, FL, explains the mechanism of action of CG0070, an adenovirus oncolytic virus, and the rationale behind combining it with pembrolizumab to treat Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer. This interview took place at the American Urological Association annual congress 2022 in New Orleans and online.
Disclosures
Research support: Predicine; Decipher Biosciences. CG Oncology.
Clinical trial protocol committee – CG Oncology;
Scientific advisor/consultant – BMS, Ferring, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence.
